Clinical Trial Results: Pancreatic Cancer

Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients with Metastatic Pancreatic Cancer.

Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: II
A study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer.

Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer.

Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: II
A Study of Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Pancreatic Cancer